(-)-反式-3-(3,4-亚甲基二氧基苄基)-2-(3,4,5-三甲氧基苄基)丁内酯
中文名称 | (-)-反式-3-(3,4-亚甲基二氧基苄基)-2-(3,4,5-三甲氧基苄基)丁内酯 |
---|---|
中文同义词 | (-)-反式-3-(3,4-亚甲基二氧基苄基)-2-(3,4,5-三甲氧基苄基)丁内酯;亚太因;化合物 T17270 |
英文名称 | (3R)-3α-(3,4,5-Trimethoxybenzyl)-4β-(1,3-benzodioxole-5-ylmethyl)tetrahydrofuran-2-one |
英文同义词 | (-)-Deoxypodorhizone;(3R)-3α-(3,4,5-Trimethoxybenzyl)-4β-(1,3-benzodioxole-5-ylmethyl)tetrahydrofuran-2-one;(3R)-3α-(3,4,5-Trimethoxybenzyl)-4β-[(1,3-benzodioxole-5-yl)methyl]-4,5-dihydrofuran-2(3H)-one;(3R,4R)-3-(3,4,5-Trimethoxybenzyl)-4-(1,3-benzodioxole-5-ylmethyl)tetrahydrofuran-2-one;(3R,4R)-3-(3,4,5-Trimethoxybenzyl)-4-[(1,3-benzodioxol-5-yl)methyl]dihydrofuran-2(3H)-one;Yatein;(+)-Deoxypodorhizon;(3S)-3β-(3,4,5-Trimethoxybenzyl)-4α-[(1,3-benzodioxole-5-yl)methyl]-4,5-dihydrofuran-2(3H)-one |
CAS号 | 40456-50-6 |
分子式 | C22H24O7 |
分子量 | 400.42 |
EINECS号 | |
相关类别 | 木脂素;标准品 -中药标准品 |
Mol文件 | 40456-50-6.mol |
结构式 |
(-)-反式-3-(3,4-亚甲基二氧基苄基)-2-(3,4,5-三甲氧基苄基)丁内酯 性质
沸点 | 564.9±45.0 °C(Predicted) |
---|---|
密度 | 1.266±0.06 g/cm3(Predicted) |
储存条件 | Store at -20°C |
溶解度 | 溶于二甲基亚砜 |
形态 | 固体 |
颜色 | 无色至浅黄 |
HSV-1
Yatein induces cell-cycle arrest at G2/M phase (5 μM; 24 hours) and enhances G2/M phase-related protein expression (5 μM; 6-12 hours) in human lung adenocarcinoma A549 and CL1-5 cells.
Yatein (5 μM; 6-12 hours) induces DNA damage through activation of the ATM/ATR pathway in human A549 and CL1-5 cells.
Yatein (5 μM; 6 hours) affects microtubule dynamics by inhibiting tubulin polymerization.
Cell Viability Assay
Cell Line: | A549 cells, CL1-5 cells |
Concentration: | 1.25 μM , 2.5 μM , 5 μM |
Incubation Time: | 24 hours |
Result: | Induced cell-cycle arrest at G2/M phase in both cell lines. |
Cell Viability Assay
Cell Line: | A549 cells, CL1-5 cells |
Concentration: | 5 μM |
Incubation Time: | 6 hours, 12 hours |
Result: | Upregulated the expression of cyclin B1, but not Cdc2 and Cdc25c, induced Cdc2 phosphorylation. |
Yatein (20 mg/kg; i.p.; five times per week; for 42 days) exhibits in vivo antitumor effects in a human lung adenocarcinoma xenograft mouse model.
Animal Model: | Male NOD/SCID mice (6-8 weeks), with A549 cells xenograft |
Dosage: | 20 mg/kg |
Administration: | Intraperitoneal injection, five times per week, for 42 days |
Result: | Significantly slowed tumor growth and moderately increased both cyclin B1 expression and Cdc2 phosphorylation. |